The most frequently occurring adverse reactions (â‰¥ 5% and greater than placebo) were nausea, headache, constipation, dizziness, insomnia, hot flush, hyperhydrosis, vomiting, palpitations, heart rate increase, dry mouth, and hypertension [FDA Savella prescribing information]. Milnacipran can have a significant impact on sexual functions, including both a decrease in sexual desire and ability{{Citation needed|reason=This claim needs a reliable source; most papers indicate the opposite.|date=March 2015}}. Milnacipran can cause pain of the testicles in men.  The incidence of cardiovascular and [[anticholinergic]] side effects was significantly lower compared to [[Tricyclic antidepressant|TCA]]s as a controlled study with over 3,300 patients revealed. Elevation of [[liver enzymes]] without signs of symptomatic liver disease has been infrequent. Mood swing to [[mania]] has also been seen and dictates termination of treatment. In [[psychotic]] patients emergence of [[delirium]] has been noticed. Milnacipran has a low incidence of [[sedation]] but improves [[sleep]] (both duration and quality) in depressed patients. In [[Psychomotor agitation|agitated]] patients or those with [[suicidal]] thoughts additive sedative/anxiolytic treatment is usually indicated.<ref>{{cite web |url=http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022256s014s015lbl.pdf |title=www.accessdata.fda.gov |format= |work= |accessdate=}}</ref>

 

